Legal Showdown Over Duchenne Drug Pricing: Capricor vs. Nippon Shinyaku

In a legal dispute that highlights the complexities of drug pricing and distribution, Capricor Therapeutics has filed a lawsuit against Nippon Shinyaku and its U.S. subsidiary, NS Pharma, alleging they have failed to follow through on marketing commitments for a Duchenne muscular dystrophy treatment. Central to the case is a critical pricing glitch in their exclusive distribution agreement that could make the therapy economically unfeasible for patients covered by government and private insurers. Here's a Q&A that breaks down the key issues.

What is the lawsuit about?

Capricor Therapeutics has taken legal action against Nippon Shinyaku and its subsidiary, NS Pharma, in a New Jersey state court. The suit claims that the Japanese company and its U.S. arm have reneged on their marketing plans for a Duchenne muscular dystrophy treatment called deramiocel. Additionally, Capricor asserts that Nippon Shinyaku has refused to rectify a fatal flaw in the pricing formula of their exclusive distribution agreement. This flaw was only disclosed in March 2025, despite being a longstanding issue. Capricor argues that this pricing error makes it economically impracticable for healthcare providers to administer the drug to patients covered by Medicare, Medicaid, and private insurers.

What is the 'fatal flaw' in the pricing formula?

The pricing flaw stems from how the exclusive distribution agreement calculates reimbursement under government programs. Under the current formula, Medicare reimbursement is tied to the price that Capricor charges NS Pharma as the sole U.S. buyer. However, the lawsuit indicates that this formula would result in healthcare providers receiving less in reimbursement than the actual cost of acquiring and administering deramiocel. In other words, providers would lose money on every dose they give to patients covered by Medicare, Medicaid, or private insurers. Capricor describes this as a fatal flaw because it creates a financial disincentive for hospitals and clinics to offer the therapy to a large portion of the patient population.

How does the pricing glitch affect patients with Medicare, Medicaid, or private insurance?

The pricing glitch directly threatens patient access to deramiocel. If healthcare providers are reimbursed less than their cost to acquire and administer the drug, they may be unwilling to provide the treatment to patients covered by these insurance plans. This could effectively exclude a significant number of Duchenne muscular dystrophy patients—especially those on Medicare and Medicaid—from receiving the therapy. Private insurers, which often follow Medicare reimbursement models, could also face similar barriers. Capricor argues that without fixing this flaw, the drug will never reach the patients who need it most, as it becomes financially unsustainable for providers to administer it.

What is deramiocel?

Deramiocel is an investigational therapy developed by Capricor Therapeutics for the treatment of Duchenne muscular dystrophy (DMD). DMD is a severe genetic disorder characterized by progressive muscle degeneration and weakness. The drug is designed to address the underlying cause of the disease by targeting specific cellular pathways. In the context of this lawsuit, deramiocel is the subject of an exclusive distribution agreement between Capricor and Nippon Shinyaku, giving the Japanese company the sole right to market and distribute the drug in the United States. The current dispute centers on whether that agreement's pricing structure makes it viable for patients to receive the drug through public and private insurance programs.

Why is Capricor accusing Nippon Shinyaku of slow-walking plans?

Capricor alleges that Nippon Shinyaku and NS Pharma have not only failed to execute the marketing strategies outlined in their distribution agreement but have also been delay tactics in addressing the pricing problem. The lawsuit claims that after disclosing the fatal flaw in March 2025, the company refused to work with Capricor to amend the pricing formula. Capricor interprets this refusal as an attempt to slow-walk the commercialization of deramiocel, possibly to avoid financial losses or renegotiate more favorable terms. By failing to fix the pricing glitch, Nippon Shinyaku is making it difficult for the drug to penetrate the market, which Capricor argues is a breach of the partnership's intent.

What does Capricor seek through the lawsuit?

In the lawsuit filed in New Jersey state court, Capricor is asking the court to compel Nippon Shinyaku and NS Pharma to honor their contractual obligations. Specifically, Capricor wants the court to order the defendants to fix the flawed pricing formula so that the therapy can be economically viable for Medicare, Medicaid, and private insurers. Additionally, Capricor is likely seeking damages for the delays in marketing and for the potential lost sales revenue. The company argues that without judicial intervention, the partnership's exclusive distribution agreement will remain commercially unworkable, leaving Duchenne patients without access to a promising treatment.

What is the background of the exclusive distribution agreement?

The exclusive distribution agreement between Capricor and Nippon Shinyaku was intended to combine Capricor's innovative drug candidate with Nippon Shinyaku's commercialization expertise and market access in the U.S. Under the deal, Nippon Shinyaku and its subsidiary NS Pharma would be the sole buyer and distributor of deramiocel. However, the agreement contained a pricing mechanism that directly linked the drug's wholesale price to the reimbursement rates set by government programs like Medicare. This mechanism turned out to be deeply flawed, as it created a scenario where providers would be reimbursed less than their costs. The glitch was reportedly discovered only after the agreement was signed and remained unaddressed until it was disclosed in March 2025, leading to the current legal dispute.